Temple Acquires Longevous for UK Expansion & Wearable Launch

Deepinder Goyal’s health-tech venture, Temple, has finalized its expansion into the United Kingdom, acquiring London-based longevity medicine practice, Longevous. This strategic move aims to integrate critical medical and scientific expertise ahead of Temple’s innovative wearable device launch.

While financial terms of the acquisition were not disclosed, the deal significantly bolsters Temple’s capabilities. The company is preparing for a broader launch of its device later this year.

• Acquired Entity: London-based Longevous, a longevity medicine practice.
• Acquirer: Deepinder Goyal’s health-tech venture, Temple.
• Purpose: Enhance medical and scientific expertise for wearable device launch.
• Financial Terms: Not disclosed.

Temple’s wearable device is designed to be worn on the side of the head. It collects physiological signals to measure ‘Entropy’, a metric quantifying the body’s real-time metabolic energy usage.

Key Leadership Joins Temple

Longevous founders, Dr. Robert Mohr and Dr. Avi Roy, will now join Temple full-time. Their specialized knowledge is crucial for the company’s commercialization efforts.

• Dr. Robert Mohr: Board-certified physician, appointed Temple’s Chief Medical Officer.
• Dr. Avi Roy: Oxford-trained biomedical scientist, takes on the role of Temple’s Head of Science.
• Combined Expertise: Preventive medicine, precision medicine, and longevity research.

The collaboration started with a chance meeting in London between Goyal, Mohr, and Roy. This initial connection deepened after Mohr and Roy experienced the Temple device firsthand.

Both founders actively contributed to the device’s validation process. Longevous will continue to serve its existing clients, now operating under Temple’s expanded umbrella.

This acquisition positions Temple to leverage specialized longevity expertise as it introduces its unique physiological tracking technology to the market.